Evofem Biosciences, Inc. (EVFM)
$0.1399
-0.01 (-6.73%)
Rating:
Recommendation:
Buy
| Symbol | EVFM |
|---|---|
| Price | $0.1399 |
| Beta | -1.238 |
| Volume Avg. | 0.11M |
| Market Cap | 30.213M |
| Shares () | - |
| 52 Week Range | 0.12-25.0 |
| 1y Target Est | - |
| DCF Unlevered | EVFM DCF -> | |
|---|---|---|
| DCF Levered | EVFM LDCF -> | |
| ROE | 62.11% | Strong Buy |
| ROA | -304.80% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -99.06% | |
| P/E | -0.11 | Neutral |
| P/B | -0.11 | Neutral |
Latest EVFM news
About
Download (Excel)Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.